Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy—Advances through 2026 Authors: Satoru Morimoto, Chris Kato, Shinichi Takahashi, Hideyuki Okano Published: 2026 ABSTRACT AbstractThree converging therapeutic paradigms—iPSC-based drug discovery, cell transplantation, and gene therapy—have substantially expanded the therapeutic pipeline for amyotrophic lateral sclerosis (ALS) between 2020 and 2026. The FDA's accelerated approval of tofersen (Qalsody) in April 2023 marked the first treatment targeting a genetic cause of ALS. iPSC-derived drug candidates, including ropinirole and bosutinib, have completed early-phase clinical trials led by Japanese institutions. Cell therapies targeting neuroinflammation through regulatory T cells are being actively explored as immunomodulatory strategies, although efficacy remains to be established in adequately powered trials. Next-generation gene-silencing approaches—including RNA interference (RNAi) therapeutics and AAV-delivered microRNA—entered first-in-human trials in 2024–2025. The identification of STMN2 as a downstream target of TDP-43 dysfunction has opened a potential TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS, which constitutes approximately 90% of all cases, with company-reported interim data suggesting target engagement in the ongoing Phase 1/2 ANQUR trial (QRL-201). This review synthesizes the latest evidence across all three therapeutic domains, with attention to the hierarchy of evidence, regulatory milestones, and the pioneering contributions of Japanese research groups.Keywords: Amyotrophic lateral sclerosis, Induced pluripotent stem cells, Cell therapy, Gene therapy, Regulatory T cell, Ropinirole Abbreviations amyotrophic lateral sclerosis ALS Functional Rating Scale–Revised antisense oligonucleotide induced pluripotent stem cell iPSC-derived motor neuron motor neuron mesenchymal stem cell neurofilament light chain phosphorylated neurofilament heavy chain neural stem cell neural progenitor cell RNA interference small interfering RNA regulatory T cell TAR DNA-binding protein 43 frontotemporal dementia dipeptide repeat cerebrospinal fluid adeno-associated virus clustered regularly interspaced short palindromic repeats Introduction Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons, leading to paralysis and death typically within 3–5 years of symptom onset. The global incidence is approximately 1–2 per 100,000, with a lifetime risk of roughly 1:300. Approximately 5–10% of cases are familial (fALS), most commonly caused by mutations in superoxide dismutase 1 (SOD1), C9orf72, fused-in sarcoma (FUS), and TARDBP encoding TDP-43, while the remaining 90–95% are classified as sporadic (sALS), though genome-wide association studies continue to identify risk loci. Until recently, riluzole (approved in 1995) and edaravone (approved in Japan and the United States in 2017) were the principal disease-modifying treatments available for ALS, both offering modest benefit. In Japan, this therapeutic landscape was further updated in September 2024 by the manufacturing and marketing approval of rozebalamin (ultra-high-dose methylcobalamin/mecobalamin) for slowing functional impairment in ALS, based on the JETALS Phase 3 randomized controlled trial in early-stage ALS, in which 50 mg intramuscular methylcobalamin administered twice weekly significantly slowed ALSFRS-R decline over 16 weeks in patients enrolled within 1 year of symptom onset and with moderate progression [1]. Since 2020, the ALS therapeutic landscape has undergone a notable shift driven by three converging approaches: (1) iPSC-based drug discovery, in which patient-derived motor neurons serve as disease models and drug-screening platforms; (2) cell therapy, encompassing mesenchymal stem cells, neural progenitor cells, and immunomodulatory regulatory T cell strategies; and (3) gene therapy, including antisense oligonucleotides (ASOs), RNA interference (RNAi), AAV-mediated gene delivery, and genome editing. The approval of tofersen for SOD1-ALS in 2023 validated the first genetically targeted therapy for ALS, while the identification of STMN2 and UNC13A as TDP-43-dependent cryptic splicing targets has raised the prospect of nucleic acid-based therapeutics applicable to sporadic ALS. This review provides a comprehensive and critically appraised survey of advances across these three domains through March 2026. Throughout, we distinguish explicitly between evidence derived from peer-reviewed publications, regulatory filings, institutional announcements, and company press releases to ensure that the reader can assess the maturity and reliability of each data point (Fig. 1). Three converging therapeutic paradigms for ALS. iPSC-based drug discovery (top left), cell therapy (bottom left), and gene therapy (right) represent the three major therapeutic domains reviewed in this article. Representative clinical-stage candidates are highlighted for each approach. Familial ALS (5–10%) is primarily driven by mutations in SOD1, C9orf72, FUS, and TARDBP; sporadic ALS (90–95%) is characterized by TDP-43 pathology leading to STMN2 and UNC13A loss. MN, motor neuron; MSC, mesenchymal stem cell; NSC, neural stem cell; ASO, antisense oligonucleotide; RNAi, RNA interference; AAV, adeno-associated virus. This article was prepared as a narrative review rather than a systematic review. Peer-reviewed literature was identified through PubMed and Google Scholar searches using combinations of the terms “amyotrophic lateral sclerosis,” “ALS,” “iPSC,” “induced pluripotent stem cell,” “motor neuron,” “cell therapy,” “stem cell therapy,” “gene therapy,” “antisense oligonucleotide,” “RNA interference,” “AAV,” “clinical trial,” and the names of specific therapeutic candidates. ClinicalTrials.gov, regulatory agency communications, company and institutional announcements, and conference abstracts were also reviewed to capture recent clinical and regulatory developments for which peer-reviewed publications were not yet available. The final update was performed in March 2026. Non-peer-reviewed sources were included only when they reported clinically relevant trial status, regulatory decisions, or interim results that were not available in the peer-reviewed literature; throughout the manuscript and figures, such information is explicitly labeled according to its source type to distinguish it from peer-reviewed evidence. iPSC-based drug discovery for ALS Disease modeling platforms The reprogramming of somatic cells from ALS patients into iPSCs, followed by directed differentiation into motor neurons (iPSC-MNs), has created an unprecedented platform for drug screening. iPSC-MNs from patients harboring mutations in SOD1, C9orf72, FUS, and TARDBP recapitulate key pathological features, including membrane hyperexcitability, TDP-43 mislocalization and cytoplasmic aggregation, mitochondrial dysfunction, and reduced survival [2,3]. Large-scale biobanking initiatives have dramatically expanded the resource base. The Answer ALS consortium generated over 1000 iPSC lines from ALS patients with integrated multi-omics data [4]. More recently, Bye et al. established an iPSC library from 100 sporadic ALS patients, 11 suspected familial cases, and 25 controls [5]. These resources enable population-scale drug screening and patient stratification that were previously impossible. Drug candidates identified through iPSC screening Ropinirole hydrochloride. A dopamine D2 receptor agonist approved for Parkinson's disease, ropinirole hydrochloride (ropinirole) was identified by the Okano laboratory at Keio University through screening of 1232 FDA-approved drugs. The compound inhibited reactive oxygen species production, reduced abnormal TDP-43/FUS aggregation, improved mitochondrial function, and prevented motor neuron death in 16 of 22 (72.7%) patient-derived iPSC-MN lines [6]. The mechanism involves suppression of the cholesterol biosynthesis pathway [7]. A subsequent study confirmed that ropinirole also functions through a dopamine receptor D2-independent mechanism in TARDBP-mutant iPSC-MNs [8]. Bosutinib. A Src/c-Abl tyrosine kinase inhibitor approved for chronic myelogenous leukemia, bosutinib was identified by the Inoue laboratory at CiRA, Kyoto University. Screening of 1416 compounds on SOD1-mutant iPSC-MNs identified hits targeting the Src/c-Abl pathway. Bosutinib promoted autophagy, reduced misfolded SOD1 accumulation, and rescued motor neuron degeneration. Importantly, it also showed efficacy in sporadic ALS iPSC models [9]. Retigabine (ezogabine). A Kv7 (KCNQ) potassium channel opener identified by the Eggan and Wainger laboratories at Harvard/Massachusetts General Hospital. ALS iPSC-MNs with SOD1, C9orf72, and FUS mutations displayed intrinsic membrane hyperexcitability, and retigabine suppressed firing across genotypes [2]. This finding led to the first clinical trial designed using iPSC model data. Combination screening. A landmark 2025 study by Bye et al. screened 107 drugs previously tested in ALS clinical trials using their 100-patient sporadic ALS iPSC library. Strikingly, 97% of compounds failed to mitigate neurodegeneration in iPSC-MNs, recapitulating clinical trial failures. A triple combination of riluzole, baricitinib (a JAK inhibitor), and memantine (an NMDA receptor antagonist) extended LD50 survival by 30.3 days (p < 0.0001), with all donors responding [5] (Fig. 2). iPSC-based drug discovery pipeline: from patient to clinical trial. Upper panel: schematic workflow from ALS patient-derived somatic cells to clinical trial via iPSC reprogramming using Yamanaka factors, directed differentiation into motor neurons (iPSC-MNs), and large-scale drug screening against compound libraries. Lower panel: key drug candidates identified through iPSC-based screening, with respective discovery laboratories, trial designs, and evidence levels. Ropinirole hydrochloride, identified by the Okano laboratory at Keio University through screening of 1232 FDA-approved compounds, acts as a dopamine D2 receptor agonist and suppresses the cholesterol biosynthesis pathway. In the ROPALS trial—a randomized, double-blind, placebo-controlled Phase 1/2a study (n = 20)—ropinirole met its primary safety endpoint; the double-blind period did not demonstrate a statistically significant difference in ALSFRS-R decline, and exploratory efficacy signals were observed only in the uncontrolled open-label extension (peer-reviewed). Bosutinib, identified by the Inoue laboratory at CiRA, Kyoto University, targets the Src/c-Abl tyrosine kinase pathway. The iDReAM Phase 2 trial was a single-arm study with a historical registry control (n = 26); both primary endpoints were reported as met in an institutional announcement, but these results should be interpreted in the context of the uncontrolled design, and peer-reviewed publication is pending. Ezogabine (retigabine), identified by the Eggan and Wainger laboratories at Harvard/MGH, targets Kv7 (KCNQ) potassium channels and reduces motor neuron hyperexcitability. In a randomized, double-blind, placebo-controlled Phase 2 trial (n = 65), the pharmacodynamic primary endpoint was met in a dose-dependent manner; the trial was not powered for clinical efficacy assessment (peer-reviewed). iPSC, induced pluripotent stem cell; iPSC-MN, iPSC-derived motor neuron; DB, double-blind; RCT, randomized controlled trial; OLE, open-label extension; PD, pharmacodynamic; EP, entire period; CiRA, Center for iPS Cell Research and Application; MGH, Massachusetts General Hospital. Clinical trials derived from iPSC drug discovery ROPALS trial (UMIN000034954). A Phase 1/2a randomized, double-blind, placebo-controlled study at Keio University Hospital enrolled 20 sporadic ALS patients (13 ropinirole, 7 placebo). Ropinirole (2–16 mg/day extended-release) met its primary safety endpoint. During the 24-week double-blind period, ALSFRS-R decline was not significantly different between groups. In the subsequent open-label extension, exploratory analyses suggested 27.9 weeks of additional disease-progression-free survival and suppression of ALSFRS-R decline in the ropinirole group; however, these findings should be interpreted cautiously given the uncontrolled design and small sample size. iPSC-MNs generated from trial participants showed a correlation between in vitro drug response and clinical outcomes [7]. K Pharma, Inc. has announced plans for Phase 3 development (company-reported). iDReAM trial (UMIN000036295; NCT04744532). Led by Imamura and Inoue at CiRA, this program evaluated bosutinib in two phases. The Phase 1 dose-escalation study (13 patients, 100–400 mg QD) demonstrated no dose-limiting toxicities up to 300 mg, with 5 of 9 evaluable patients (55.6%) showing disease stabilization. Single-cell RNA sequencing of participant iPSC-MNs revealed molecular signatures distinguishing responders, and lower baseline plasma NfL predicted response [10]. The Phase 2 study (26 patients, 200–300 mg QD, 24 weeks) was reported to have met both primary endpoints in a CiRA institutional announcement (July 2024); however, the peer-reviewed publication is pending, and the full data set has not yet been made available for independent evaluation [CiRA press release, July 18, 2024]. The Phase 2 protocol was published in BMJ Open (2024). Ezogabine Phase 2 trial (NCT02450552). Conducted across 12 NEALS consortium sites, this trial enrolled 65 ALS patients receiving ezogabine 600 mg/day, 900 mg/day, or placebo for 10 weeks. The trial met its primary pharmacodynamic endpoint: ezogabine reduced motor neuron excitability in a dose-dependent manner as measured by threshold-tracking nerve conduction studies. The trial was not powered for clinical efficacy [11]. Patient-specific modeling and precision medicine The integration of iPSC phenotyping with clinical data points toward precision medicine in ALS. The ROPALS trial demonstrated a correlation between in vitro ropinirole response in iPSC-MNs and clinical disease trajectory [7]. On the other hand, the iDReAM trial linked iPSC-derived single-cell transcriptomic signatures to bosutinib responsiveness [10]. The Bye et al. (2025) study further showed that individual donor responses to combination therapy varied markedly, reinforcing the rationale for personalized treatment strategies. While these associations are intriguing, prospective validation in larger cohorts is needed before iPSC-based pharmacogenomic stratification can be incorporated into clinical decision-making. Cell therapy for ALS Mesenchymal stem cell therapies NurOwn (debamestrocel/MSC-NTF). Developed by BrainStorm Cell Therapeutics, NurOwn consists of autologous bone marrow-derived MSCs differentiated to secrete neurotrophic factors (GDNF, BDNF, VEGF, HGF), administered intrathecally. The Phase 3 trial (NCT03280056, approximately 200 participants) did not meet its primary endpoint: 34.7% of NurOwn-treated versus 27.7% of placebo patients achieved ≥1.25-point ALSFRS-R slope improvement (p = 0.453). A pre-specified subgroup with baseline ALSFRS-R ≥35 showed a stronger but non-significant signal (34.6% vs. 15.6%). CSF biomarker analysis demonstrated significant VEGF increases and MCP-1 decreases [12]. An FDA advisory committee voted 17–1–1 against approval in September 2023, and the BLA was subsequently withdrawn. A new Phase 3b trial (ENDURANCE; NCT06973629) under Special Protocol Assessment received FDA clearance in 2025, planning to enroll approximately 200 participants earlier in disease course (company-reported). Expanded access data from 10 Phase 3 completers showed that 9 of 10 survived beyond 5 years from symptom onset (the single death was due to elective euthanasia), with a median survival of 6.8 years (range: 6–7 years); however, these are uncontrolled data from a small cohort of patients who entered the trial relatively early (mean baseline ALSFRS-R 35.8), and they have not been peer-reviewed [BrainStorm press release, June 16, 2025]. Lenzumestrocel (Neuronata-R). Developed by CORESTEMCHEMON (South Korea), this product received conditional approval in South Korea in December 2013. The Phase 2 RCT (NCT01363401, 64 patients) showed significantly slowed ALSFRS-R decline at 4 and 6 months [13]. The Phase 3 ALSUMMIT trial (NCT04745299) did not meet its primary composite CAFS endpoint in the overall population. However, post hoc analysis revealed statistically significant improvement in the slow-progressor subgroup at 6 months (Group 1: LS mean CAFS 20.95 vs. 13.66, p < 0.024; Group 2: LS mean 24.78 vs. 17.92, p < 0.041), with NfL levels significantly lower than placebo in the five-dose arm at months 4 and 10 (company-reported; presented at PACTALS 2025). CorestemChemon has announced plans to pursue FDA accelerated approval based on the subgroup data and NfL biomarker precedent, with a BLA submission targeted for 2026; however, the path from a post hoc subgroup analysis to FDA approval remains uncertain and should not be treated as a foregone conclusion. Neural stem cells and combined cell–gene therapy CNS10-NPC-GDNF. Developed at Cedars-Sinai Medical Center, this approach uses allogeneic human neural progenitor cells transduced with the GDNF gene, designed to differentiate into GDNF-secreting astrocytes in situ. The Phase 1/2a spinal cord trial (NCT02943850, 18 participants) met its primary safety endpoint. Post-mortem analysis of 13 participants demonstrated graft survival and GDNF production up to 42 months post-transplantation, providing the most compelling proof-of-concept for durable combined cell–gene therapy in ALS [[14], [15], [16]]. A Phase 1 motor cortex trial (NCT05306457) is ongoing. NSI-566. Human spinal cord-derived neural stem cells (Neuralstem/Seneca Biopharma) completed Phase 1 (NCT01348451) and Phase 2 (NCT01730716) trials with demonstrated safety from direct intraspinal injection. Phase 3 planning was discussed with FDA, though the company's current development status is uncertain. AstroRx. Human embryonic stem cell-derived astrocytes (Kadimastem), administered intrathecally, showed transient ALSFRS-R improvement in a Phase 1/2a trial (NCT03482050, 10 patients). The low-dose group slowed from −0.88 to −0.30 points/month (p = 0.039), but the effect was not sustained beyond 5–6 months [17]. Regulatory T cell therapy Neuroinflammation with dysfunctional Regulatory T cells (Tregs) is increasingly recognized as a contributor to ALS progression. Rapid disease progression has been correlated with decreased FoxP3 expression and Treg frequency, and Treg suppressive function can be restored by ex vivo expansion [18]. Phase 1 studies of expanded autologous Tregs with IL-2 in 3 ALS patients showed slowing of progression during infusions, with acceleration upon cessation [19]. COYA 302 (Coya Therapeutics). A combination of low-dose IL-2 and CTLA-4 Ig for subcutaneous self-administration. Phase 1 data (NCT06307301, 4 patients) showed improvement in ALSFRS-R slope during the 24-week treatment period compared with pre-treatment decline, as reported in a peer-reviewed publication [20]. Given the very small sample size and open-label design, these results require confirmation. The Phase 2 ALSTARS trial (NCT07161999, 120 patients) was launched in the second half of 2025 and dosing has begun (company-reported). RAPA-501 (Rapa Therapeutics). Autologous hybrid TREG/Th2 cells manufactured via epigenetic reprogramming. A Phase 2/3 trial (NCT04220190) and an NIH-funded expanded access program (NCT06169176) are ongoing at multiple U.S. sites. MIROCALS trial. This Phase 2b study (220 patients, 17 UK/French clinics) demonstrated that low-dose IL-2 alone safely increased Treg numbers but did not show efficacy as a universal ALS treatment in the broad population. A post hoc biomarker-defined subgroup with slower progression showed a potential benefit signal [21]. These results indicate that Treg-based immunomodulation may require patient selection or combination strategies to be effective. iPSC-derived cell therapies entering clinical translation Shanghai East Hospital has initiated a clinical study of iPSC-derived motor neuron precursors (NCT06765564; registry-listed). In 2025, three iPSC-based therapies targeting Parkinson's disease, spinal cord injury, and ALS received FDA IND clearance (company/institutionally announced). As of December 2024, 115 global clinical trials involving 83 distinct pluripotent stem cell-derived products have been reported, encompassing over 1200 dosed patients [22]. While these milestones are encouraging, iPSC-derived cell therapy for ALS remains at a very early stage, and efficacy data are not yet available. Gene therapy for ALS Tofersen: establishing the ASO paradigm for genetic ALS Tofersen (Qalsody, BIIB067), developed by Biogen and Ionis Pharmaceuticals, is a 20-mer gapmer ASO with 2′-O-methoxyethyl modifications that targets SOD1 mRNA for RNase H-mediated degradation, administered intrathecally at 100 mg every 28 days after a loading regimen. VALOR trial (NCT02623699). The Phase 3 study (108 participants, 2:1 randomization) did not meet its primary endpoint: the difference in ALSFRS-R change was −1.2 points (tofersen −6.98 vs. placebo −8.14; p = 0.97, one-sided). However, tofersen achieved a 35% reduction in CSF SOD1 protein and a 55% reduction in plasma NfL, compared with a 12% NfL increase in the placebo group [23]. The open-label extension (OLE) revealed an early-start benefit: participants initiating tofersen 6 months earlier showed a 3.5-point ALSFRS-R advantage at 12 months and a hazard ratio for death or permanent ventilation of 0.36 (95% CI: 0.14–0.94). Long-term OLE data with up to 5.4 years of follow-up were published in JAMA Neurology (December 2025), reporting that in faster-progressing participants, early tofersen initiation was associated with an estimated 3.4-year extension of event-free survival. Regulatory approvals. Tofersen received FDA accelerated approval on April 25, 2023, based on plasma NfL reduction as a surrogate biomarker—the first such use of NfL in a regulatory decision. The European Commission granted marketing authorization under exceptional circumstances on May 29, 2024. Additional approvals followed in Canada (March 2025) and the United Kingdom (July 2025). Australia's Therapeutic Goods Administration has accepted the submission for evaluation, though the precise regulatory status should be confirmed with the TGA directly. ATLAS trial (NCT04856982). The first interventional trial in presymptomatic ALS is evaluating tofersen in approximately 150 presymptomatic SOD1 variant carriers with elevated plasma NfL (≥44 pg/mL). Results are expected around 2027; this study also serves as the confirmatory trial for the FDA accelerated approval [24]. Lessons from discontinued ASO programs Several ASO programs targeting non-SOD1 genetic ALS have been terminated despite achieving target engagement, highlighting the complexity of ALS pathophysiology. BIIB078 (Ionis/Biogen). Targeting C9orf72 sense RNA transcripts, this program was discontinued in March 2022 after Phase 1 (NCT03626012) showed no clinical benefit despite CSF dipeptide repeat (DPR) protein reductions. Post-mortem analyses revealed inadequate tissue-level target suppression, persistence of phosphorylated TDP-43 pathology, and sustained neuroinflammatory markers including CCL26 despite CSF DPR reductions [25]. WVE-004 (Wave Life Sciences). A stereopure ASO selectively targeting C9orf72 repeat-containing transcripts achieved approximately 50% poly(GP) DPR reduction (p < 0.001) in the FOCUS-C9 trial (NCT04931862) but showed no clinical benefit and was discontinued in May 2023. BIIB105/ION541 (Ionis/Biogen). Targeting ATXN2, this ASO achieved statistically significant CSF ataxin-2 reductions in the ALSpire trial (NCT04494256) but showed no NfL reduction or clinical improvement and was terminated in May 2024. These failures underscore a critical principle: achieving molecular target engagement does not guarantee clinical benefit in ALS. The disconnect between biomarker changes and functional outcomes suggests mechanisms more complex than simple toxic gain-of-function, particularly for C9orf72. Jacifusen for FUS-ALS Jacifusen (ulefnersen, ION363), an ASO targeting FUS pre-mRNA, has shown the most striking individual clinical responses among ASO therapies to date. In an expanded access case series of 12 FUS-ALS patients (median treatment 9.3 months), NfL was reduced by up to 82.8%, and post-mortem tissue analysis showed 66–90% FUS protein reduction [26,27]. One patient showed unprecedented functional recovery, with ALSFRS-R improving from 8 to approximately 20 points after initial decline, regaining walking and independent breathing. A presymptomatic carrier has remained asymptomatic after 3 years of treatment. The Phase 3 FUSION trial (NCT04768972, approximately 95 patients) completed enrollment in August 2025, with results expected in the second half of 2026 (company-reported timeline). STMN2 restoration: a potential nucleic acid therapeutic avenue for sporadic ALS The most significant emerging target is STMN2 (stathmin-2), essential for axonal stability. Loss of nuclear TDP-43 function causes cryptic exon inclusion in STMN2 pre-mRNA, leading to premature polyadenylation and loss of full-length protein. Because TDP-43 pathology occurs in approximately 97% of all ALS cases, STMN2 restoration could theoretically benefit the vast majority of patients [28,29]. QRL-201 (QurAlis). A first-in-class ASO designed to restore STMN2 expression by redirecting splicing. The ANQUR Phase 1/2 trial (NCT05633459) dosed its first patient in October 2024 (company-reported). Interim results announced by the company in February 2026 reported confirmed target engagement with statistically significant STMN2 increases, correction of STMN2 mis-splicing, statistically significant pNfH reduction, and an encouraging trend of slowed ALSFRS-R decline. These are company-reported interim data from a small, early-phase trial; the results have not been peer-reviewed, and definitive conclusions regarding efficacy cannot be drawn at this stage. A pivotal Phase 3 trial is planned for 2027 (company-reported). UNC13A. Another TDP-43-dependent cryptic exon target essential for synaptic neurotransmitter release, UNC13A has recently advanced from a preclinical concept into early clinical translation [30]. Following Lilly's 2024 licensing agreement with QurAlis for QRL-204, a splice-switching ASO designed to restore UNC13A function, the related clinical candidate LY4256984 entered a Phase 1 study in participants with sporadic ALS (NCT07100119). According to the official trial listing, this intrathecal multiple-ascending-dose study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY4256984 in approximately 32 participants with sporadic ALS. As of March 2026, no efficacy data have been publicly disclosed, and the program remains at an early dose-escalation stage. In parallel, additional UNC13A-restoring ASO programs are advancing toward clinical evaluation. Trace Neuroscience’s TRCN-1023, an investigational ASO designed to restore UNC13A expression by correcting UNC13A mis-splicing downstream of TDP-43 dysfunction, is supported by nonclinical data and is planned for evaluation in the international, multicenter, randomized, double-blind, placebo-controlled Phase 1/2 FUNCtion ALS trial, underscoring growing interest in UNC13A restoration as a TDP-43-downstream therapeutic strategy. Next-generation gene silencing: RNAi and AAV-delivered miRNA RAG-17 (Ractigen Therapeutics). RAG-17 is an investigational siRNA therapeutic designed using Ractigen’s SCAD delivery platform to target and silence SOD1 mRNA in patients with SOD1-mutated ALS. A first-in-human, investigator-initiated, open-label Phase 1 dose-escalation trial (NCT05903690) enrolled six patients with SOD1-ALS. Results presented at the American Academy of Neurology Annual Meeting 2025 (abstract S5.003) reported a greater than 50% reduction in CSF SOD1 protein in five of six patients, an average ALSFRS-R decline of 0.29 points per month, significant reductions in plasma neurofilament light chain, and no dose-limiting toxicities or serious adverse events. These findings were presented as conference data and have not yet been published in a peer-reviewed full-length article. A subsequent randomized, double-blind, placebo-controlled Phase 1 study (NCT06556394) was initiated in December 2024, followed by Ractigen’s announcement in January 2026 that the first patient had been dosed in a Phase II multiple-ascending-dose trial of repeated intrathecal RAG-17 administration. ALN-SOD (Regeneron/Alnylam). Utilizing the C16-siRNA conjugate platform, this candidate entered Phase 1 (NCT06351592) in August 2024. Preclinical di-siRNA compounds showed potency exceeding that of tofersen in cellular assays and extended lifespan in SOD1-G93A mice [31]. AMT-162 (uniQure). An AAVrh10-delivered artificial microRNA targeting SOD1, representing a potential one-time treatment paradigm. The Phase 1/2 EPISOD1 trial (NCT06100276) dosed its first patient in October 2024, with the independent data monitoring committee issuing a favorable recommendation (company-reported). This builds on the pioneering work of Mueller et al. demonstrating >90% SOD1 reduction in lumbosacral spinal cord following intrathecal AAVrh10-miR-SOD1 infusion [32]. CRISPR and genome editing: preclinical promise CRISPR/Cas9 gene disruption of mutant SOD1 in transgenic mice has demonstrated prevention of ALS-like pathology, with no evidence of disease beyond 2 years [33]. For C9orf72-ALS, paired guide RNA-mediated excision of the hexanucleotide repeat expansion in patient-derived iPSC motor neurons and brain organoids reduced RNA foci and dipeptide repeat proteins [34]. Cytosine base editing using split-intein dual-AAV delivery reduced SOD1 mRNA and extended survival in hSOD1-G93A mice, representing an early demonstration of base editing in an ALS model [35]. No CRISPR-based clinical trials for ALS have been initiated as of March 2026. Targeting TDP-43 proteinopathy directly VTx-002 (VectorY Therapeutics). An AAV-delivered vectorized antibody targeting TDP-43 aggregates. According to company announcements, VTx-002 received FDA Fast Track designation in January 2026, and the first participant was dosed in the Phase 1/2 PIONEER-ALS trial on February 9, 2026, at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The multicenter, open-label, dose-escalation study is expected to enroll 12 adults with ALS across the U.S., Europe, and the U.K. This represents the first clinical evaluation of a therapy designed to target TDP-43 proteinopathy, which is present in approximately 97% of ALS cases. No efficacy data are yet available; the trial is in its earliest dose-escalation stage (Fig. 3). Timeline of key milestones in ALS therapeutics (2020–2026). Representative advances and setbacks across gene-targeted therapies, iPSC-based drug discovery, and cell/immunomodulatory approaches are shown chronologically. Milestones above the axis indicate favorable progression events, including first-in-human dosing, clinical readouts, regulatory approvals, and public interim updates, whereas milestones below the axis indicate program discontinuation, trial termination, or market withdrawal. Color coding reflects the highest level of public support for each entry: green, peer-reviewed publication; blue, regulatory decision or approval; orange, company or institutional announcement, conference abstract, or trial-listing–based public update; red, program discontinuation or product withdrawal. Labels identify the candidate or program, the associated trial or event, and the primary public source. Where relevant, important interpretive limitations are noted, including registry-controlled designs and early interim, non–peer-reviewed readouts. ASO, antisense oligonucleotide; FDA, Food and Drug Administration; FUS, fused in sarcoma; IL-2, interleukin-2; Ph, phase; siRNA, small interfering RNA; SOD1, superoxide dismutase 1; STMN2, stathmin-2; TDP-43, TAR DNA-binding protein 43. Personalized ASOs. The Silence ALS program (Columbia University/n-Lorem Foundation) is developing custom-designed ASOs for ultra-rare ALS mutations. The first patient, harboring a mutation in CHCHD10 gene, encoding a protein primarily involved in maintaining mitochondrial structure and function, was treated in March 2024. As of the latest publicly available information, 9 of 11 enrolled patients have been dosed. The program has reported acceptable safety and tolerability; however, it is too early for definitive efficacy assessment, and the claim of disease progression slowing has not been substantiated in peer-reviewed data (Fig. 4). Selected clinical-stage ALS therapeutics across modalities, their current development stage, and the maturity of public evidence are summarized in Table 1. Genetically targeted therapeutic modalities for ALS. The left panel summarizes representative therapeutic strategies for familial or genotype-defined ALS (5–10% of all ALS cases), focusing on direct gene silencing or editing approaches targeting SOD1, FUS, and C9orf72. The right panel summarizes emerging strategies for TDP-43 proteinopathy-associated ALS, including downstream restoration of STMN2 and UNC13A and direct targeting of TDP-43. For each target, representative modalities and current development status are shown, spanning approved therapies, ongoing clinical programs, discontinued programs, and preclinical approaches. TDP-43 proteinopathy is present in most ALS cases, including most sporadic ALS and many C9orf72-associated cases, but is generally absent in SOD1-ALS and FUS-ALS; STMN2 and UNC13A dysregulation are downstream consequences of TDP-43 loss of function. ALS, amyotrophic lateral sclerosis; ASO, antisense oligonucleotide; SSO, splice-switching oligonucleotide; siRNA, small interfering RNA; AAV, adeno-associated virus. Table 1Selected ALS therapeutic pipeline by development stage and public evidence level (March 2026). Representative clinical-stage candidates are organized by therapeutic category, including gene silencing, direct targeting, iPSC-based drug discovery, cell therapy, and immunomodulation. For each candidate, the modality, molecular target or mechanistic axis, current phase or regulatory status, and highest level of publicly available support are shown. Public evidence level includes regulatory approval, peer-reviewed publication, registry listing, and institution- or company-reported updates. Discontinued or market-withdrawn candidates are listed separately below the table. ALS, amyotrophic lateral sclerosis; ASO, antisense oligonucleotide; SSO, splice-switching oligonucleotide; siRNA, small interfering RNA; AAV, adeno-associated virus; miRNA, microRNA; MSC-NTF, mesenchymal stem cell–derived neurotrophic factor–secreting cells; NPC, neural progenitor cell; GDNF, glial cell line-derived neurotrophic factor; hESC, human embryonic stem cell; Treg, regulatory T cell; IL-2, interleukin-2; CTLA4-Ig, cytotoxic T-lymphocyte antigen 4–immunoglobulin fusion protein.Table 1 Selected ALS therapeutic pipeline by development stage and public evidence level (March 2026). Representative clinical-stage candidates are organized by therapeutic category, including gene silencing, direct targeting, iPSC-based drug discovery, cell therapy, and immunomodulation. For each candidate, the modality, molecular target or mechanistic axis, current phase or regulatory status, and highest level of publicly available support are shown. Public evidence level includes regulatory approval, peer-reviewed publication, registry listing, and institution- or company-reported updates. Discontinued or market-withdrawn candidates are listed separately below the table. ALS, amyotrophic lateral sclerosis; ASO, antisense oligonucleotide; SSO, splice-switching oligonucleotide; siRNA, small interfering RNA; AAV, adeno-associated virus; miRNA, microRNA; MSC-NTF, mesenchymal stem cell–derived neurotrophic factor–secreting cells; NPC, neural progenitor cell; GDNF, glial cell line-derived neurotrophic factor; hESC, human embryonic stem cell; Treg, regulatory T cell; IL-2, interleukin-2; CTLA4-Ig, cytotoxic T-lymphocyte antigen 4–immunoglobulin fusion protein. Japanese contributions and the regulatory framework Japan's position in ALS therapeutics stems from its foundational iPSC technology, dedicated research infrastructure, and progressive regulatory framework. CiRA at Kyoto University, established following Shinya Yamanaka's Nobel Prize-winning iPSC discovery, has produced the bosutinib program, while the Okano laboratory at Keio University identified ropinirole. Both programs have advanced to clinical trials, representing the most mature examples of the iPSC drug discovery-to-clinic pipeline globally. Japan's regulatory framework provides two key pathways. The Act on the Safety of Regenerative Medicine, promulgated in 2013 and enforced in 2014, was amended in June 2024, with the amendments taking effect on May 31, 2025. The amended Act expanded its scope to include in vivo gene therapy and other nucleic-acid–based medical technologies; these are generally handled as First-Class regenerative medicine under the Act, with viral vector–based approaches such as AAV also requiring additional Cartagena Act review where applicable. Separately, the PMD Act provides a conditional and time-limited approval pathway for regenerative medicine products, allowing marketing authorization based on presumed efficacy and acceptable safety, with an initial approval period of up to 7 years and a possible extension of up to 3 additional years when necessary. The ROPALS trial protocol was published in Regenerative Therapy [36]. Discussion: challenges and future directions The field faces several unresolved challenges. The discontinuation of multiple ASO programs (BIIB078, WVE-004, BIIB105) despite achieving molecular target engagement has demonstrated that target validation alone does not ensure therapeutic success, and that ALS pathophysiology—particularly in non-SOD1 genetic subtypes—remains incompletely understood. The withdrawal of AMX0035/Relyvrio from the market in April 2024 after the Phase 3 PHOENIX trial failure further underscores the difficulty of translating early-phase signals into confirmed efficacy. Nonetheless, several developments offer grounds for cautious optimism. The identification of STMN2 and UNC13A as TDP-43-downstream targets that could, in principle, address sporadic ALS represents a conceptual breakthrough, though clinical validation is in its earliest stages. The entry of RNAi and AAV-based gene therapies into clinical testing diversifies the gene-silencing toolkit beyond ASOs. The advancement of Regulatory T cell (Treg)-based immunomodulation provides a mechanistically distinct approach to disease modification. The maturation of iPSC-based precision medicine—exemplified by the ROPALS and iDReAM trials’ use of patient-derived neurons for pharmacogenomic correlation—lays groundwork for more rational trial design. Critical priorities for the field include: (1) prospective validation of biomarker-driven patient selection strategies (NfL-guided tofersen initiation, iPSC-based responder identification) in adequately powered trials; (2) resolution of the target engagement–clinical benefit disconnect, particularly for C9orf72; (3) development of scalable manufacturing and delivery solutions for cell and gene therapies; and (4) establishment of regulatory pathways that can accommodate the unprecedented diversity of modalities now in the ALS pipeline. Conclusion The period from 2020 to 2026 has expanded the ALS therapeutic pipeline from two modestly effective drugs to a field with an approved genetically targeted therapy, multiple gene and cell therapy programs in clinical testing, and a growing roster of iPSC-discovered drug candidates approaching later-stage evaluation. Three observations from this period are particularly noteworthy. First, the tofersen experience suggests that early intervention—ideally presymptomatic—may be essential for maximizing benefit from gene-targeted therapies, as evidenced by the substantial event-free survival advantage observed with a 6-month head start in the VALOR OLE. The ongoing ATLAS presymptomatic trial will provide definitive evidence on this question. Second, the discovery of STMN2 and UNC13A as TDP-43-dependent cryptic splicing targets has, for the first time, opened a credible TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS. While QRL-201's interim data are encouraging, they remain company-reported and require peer-reviewed confirmation in larger trials before the clinical significance of this approach can be assessed. Third, iPSC-based drug discovery has matured from a laboratory technique to a clinically tested platform, with both ropinirole and bosutinib showing early clinical signals that correlate with patient-specific in vitro responses. Whether this correlation can be prospectively validated and translated into approved therapeutics remains to be determined. The central challenge ahead is to translate these advances into approved therapies for the approximately 90% of ALS patients who currently lack genetically targeted treatment options. Achieving this goal will require rigorous clinical trial design, transparent reporting of evidence at all maturity levels, and continued integration of basic science discoveries with clinical development. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work, the authors used ChatGPT as an AI-assisted tool for English language editing and literature searching. After using this tool, the authors critically reviewed and edited the content as needed and take full responsibility for the content of the published article. Funding This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Nos. JP21H05278, JP22K15736, and JP25H00007 to S.M.; JP26K10434 to S.T.; and JP26H02431 to H.O.), the Japan Agency for Medical Research and Development (AMED) (Grant Nos. JP23bm1123046, JP23kk0305024, and JP25ek0109811 to S.M.; and JP21wm0425009, JP22bm0804003, JP22ek0109616, JP23bm1423002, and JP25wm0625519 to H.O.), the Japan Intractable Diseases (Nanbyo) Research Foundation (2024A04), the Inamori Foundation, the ONO Medical Research Foundation, The Nakatomi Foundation, and the MDSJ Research Grant to S.M. Declaration of competing interest The authors declare the following financial interests/personal relationships that may be considered potential competing interests: Satoru Morimoto reports that administrative support was provided by Keio University. Hideyuki Okano reports a relationship with K Pharma, Inc. that includes board membership. Hideyuki Okano reports a relationship with Sanbio Co., Ltd. that includes consulting or advisory roles. Hideyuki Okano has a patent for a therapeutic agent for amyotrophic lateral sclerosis and a composition for treatment, which has been licensed to K Pharma, Inc. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes Peer review under responsibility of the Japanese Society for Regenerative Medicine. This article is written by the recipient of the 2026 JSRM Awards (Clinical Researches). References